Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection
AIDS, Volume 28, No. 14, Year 2014
Notification
URL copied to clipboard!
Description
Background: Children with perinatally acquired HIV (paHIV) remain at an increased risk of pneumococcal infection despite highly active antiretroviral therapy (HAART). Beyond infancy, responses to pneumococcal conjugate vaccine (PCV) remain underinvestigated. There are currently no published data on serological response to 13-valent PCV (PCV13) in the HIV-infected populations. Methods: We measured pneumococcal serotype-specific IgG in 48 paHIV-infected child patients (CP), 27 young adult healthy controls (AHC) and 30 child healthy controls (CHC). Opsonophagocytic assay (OPA) titres for three PCV13-exclusive serotypes were measured in a subset of children. Serotype-specific IgG was repeated 1 and 6 months following PCV13 vaccination of CP and AHC groups. OPA titres for four serotypes were measured at the 1-month time-point. Results: The majority of CP, CHC and AHC had serotype-specific IgG above 0.35μg/ml at baseline, although OPA activity was undetectable for two of the three serotypes studied. Baseline IgG concentrations were significantly lower in CP than AHC for a proportion of serotypes and were strongly predictive of responses to vaccine. After adjusting for baseline, postvaccination IgG concentrations were comparable, although responses to some serotypes were impaired for CP. OPA correlated well with IgG after vaccination. Detectable HIV viral load was associated with significantly lower IgG concentration and OPA titre. Conclusion: Children with paHIV mount a robust serological response to PCV13 for most but not all vaccine serotypes. Viral load suppression with HAART and higher baseline IgG concentration are associated with higher postvaccination antibody levels. This has implications for HAART treatment and vaccination practices. © 2014 Wolters Kluwer Health.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC4166014/bin/aids-28-2033-s001.doc
Authors & Co-Authors
Bamford, A. R.J.
United Kingdom
Section of Paediatrics
Kelleher, Peter W.
United Kingdom, London
Imperial College London
Lyall, Hermione
United Kingdom, London
Imperial College Healthcare Nhs Trust
Haston, Mitch
United Kingdom, London
Ucl Great Ormond Street Institute of Child Health
Zancolli, Marta
United Kingdom, London
Ucl Great Ormond Street Institute of Child Health
Goldblatt, David L.
United Kingdom, London
Ucl Great Ormond Street Institute of Child Health
Kampmann, Beate B.
United Kingdom
Section of Paediatrics
Gambia, Bathurst
Mrc Unit
Statistics
Citations: 25
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1097/QAD.0000000000000385
e-ISSN:
14735571
Research Areas
Infectious Diseases
Maternal And Child Health